(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -3.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Sarepta Therapeutics's revenue in 2025 is $2,233,371,000.On average, 10 Wall Street analysts forecast SRPT's revenue for 2025 to be $217,676,255,103, with the lowest SRPT revenue forecast at $187,599,060,844, and the highest SRPT revenue forecast at $246,724,488,836. On average, 10 Wall Street analysts forecast SRPT's revenue for 2026 to be $198,455,724,569, with the lowest SRPT revenue forecast at $114,468,271,299, and the highest SRPT revenue forecast at $248,002,090,252.
In 2027, SRPT is forecast to generate $201,168,760,315 in revenue, with the lowest revenue forecast at $132,353,904,907 and the highest revenue forecast at $261,249,834,166.